• Eliquis (Apixaban) Medical Record Review & Outsourcing Services

Eliquis (Apixaban) is an oral antiplatelet belonging to the class of direct factor Xa inhibitors. It is manufactured by Bristol-Myers Squibb and Pfizer under the trade name Eliquis. It acts by inhibiting Factor Xa, which is a key blood clotting protein that decreases the level of a thrombin, thus Eliquis indirectly decreases clot formation. Eliquis was approved by the U.S Food and Drug Administration FDA on December 28, 2012, for the prevention of stroke in people with Atrial fibrillation.

Eliquis is used for

  • Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation
  • Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
  • Treatment of Deep Vein Thrombosis
  • Treatment of Pulmonary Embolism
  • Reduction in the Risk of Recurrence of DVT and PE

In June 2014, a patient started on Eliquis died of gastrointestinal bleeding as a complication within two months. It was observed that Eliquis can increase the risk of uncontrollable bleeding, and is more prone when taken at the same time with Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).

There has been no recall of Eliquis as of November 2017.

Eliquis does not have an antidote to stop the bleeding complications.

Serious Alleged Injuries may include:

  • Gastrointestinal (GI) bleeding
  • Rectal bleeding
  • Kidney bleeding
  • Cerebral hemorrhage
  • Hypovolemic shock
  • Death


2012 Black Box warning: discontinuing Eliquis in patients without adequate continuous anticoagulation increases the risk of stroke.

2014: Another boxed warning for Eliquis to include a warning for a spinal/epidural hematoma in patients treated with Eliquis who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis.

Legal Updates:

The first lawsuit against Eliquis was filed in July 2015. The manufacturers claim that the Eliquis is superior in safety and effectiveness as compared to Warfarin, but there is a lack of clear evidence in its support.

In February 2017, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated pending Eliquis lawsuits into a multidistrict litigation (MDL No. 2754- IN RE: Eliquis (Apixaban) Products Liability Litigation under Judge Denise Cote) in the Southern District of New York. The MDL was assigned to Cote to litigate the pending actions in various locations.


  • Usage of Eliquis
  • Duration of Eliquis usage
  • Indication for Eliquis usage
  • Complications and treatment after Eliquis usage

Medical Record Review and claim validation of Eliquis case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.



Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...


NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...



CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...


CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...


NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

Valentine's Day Celebration @ Neural IT, 2019!
Neural IT celebrates Valentine's Day each year to convey heartfelt thanks and appreciation to all
Neural IT celebrated its Quarterly Program 'Rewards & Recognition: 2019'
Neural IT celebrated its Quarterly Program 'Rewards & Recognition: 2019,'  a motivational pra
Neural IT New Year Bash 2019
As we welcome year 2019, we also welcome 12 new chapters, 365 new chances.

Latest Tweets